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Summary: 
Background  
In animal models, cannabinoid-1 receptor (CBB1) blockade produces a lean phenotype, with resistance to diet-
induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on 
bodyweight and cardiovascular risk factors in overweight or obese patients. 
Methods  
1507 patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated 
or untreated dyslipidaemia, hypertension, or both, were randomised to receive double-blind treatment with 
placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day 
deficit). The primary efficacy endpoint was weight change from baseline after 1 year of treatment in the 
intention-to-treat population. 
Findings  
Weight loss at 1 year was significantly greater in patients treated with rimonabant 5 mg (mean -3 · 4 kg [SD 5·7]; 
p=0·002 vs placebo) and 20 mg (-6·6 kg [7·2]; p<0·001 vs placebo) compared with placebo (-1·8 kg [6·4]). 
Significantly more patients treated with rimonabant 20 mg than placebo achieved weight loss of 5% or greater 
(p<0·001) and 10% or greater (p<0·001). Rimonabant 20 mg produced significantly greater improvements than 
placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the 
metabolic syndrome. The effects of rimonabant 5 mg were of less clinical significance. Rimonabant was 
generally well tolerated with mild and transient side effects. 
Interpretation  
CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant 
decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors. 
 
Introduction 
The prevalence of obesity continues to increase, with more than 50% of Europeans currently classified as 
overweight and up to 30% as clinically obese.1,2 WHO has estimated that, yearly, about a quarter of a million 
deaths in Europe and more than 2·5 million deaths worldwide are weight-related, with cardiovascular disease as 
the leading cause.3 Because few safe and effective drugs are available, the treatment of obesity remains one of 
the greatest unmet clinical needs of our time. 
The newly discovered endocannabinoid system contributes to the physiological regulation of energy balance, 
food intake, and lipid and glucose metabolism through both central and peripheral effects.4-6 This system consists 
of endogenous ligands and two types of G-protein-coupled cannabinoid receptors: CBB1; located in several brain 
areas and in a variety of peripheral tissues including adipose tissue, the gastrointestinal tract, the pituitary and 
adrenal glands, sympathetic ganglia, heart, lung, liver, and urinary bladder;  and CB27,8 B , in the immune system.9 
The endocannabinoid system is overactivated in genetic animal models of obesity5 and in response to exogenous 
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stimuli such as excessive food intake.10 Preclinical studies implicate the endocannabinoid system in the 
modulation of food intake and adipogenesis,11-13 through peripheral mechanisms. The system might provide a 
possible treatment target for high-risk overweight or obese patients. Insights into the endocannabinoid system 
have been derived from studies in animals with genetic deletion of CBB1; which have a lean phenotype and are 
resistant to diet-induced obesity and associated insulin resistance produced by a highly palatable high-fat diet.  14
Further evidence comes from investigation of pharmacological blockade of CB1B  receptors with the selective CB1 
blocker rimonabant, which produces weight loss and ameliorates metabolic abnormalities in obese animals.10,15 
Preclinical findings support the role of the CBB1 receptor in both central and peripheral regulation of energy 
balance and body weight,  providing a mechanistic basis for the clinical development of rimonabant for the 5
management of obesity and associated cardiovascular risk factors. 
We undertook a large, multicentre, multi-national, randomised, placebo-controlled trial—the RIO (Rimonabant 
In Obesity) Europe trial—to assess the efficacy and safety of rimonabant in reducing body weight and improving 
cardiovascular risk factors in overweight or obese patients. 
Methods 
Patients 
Men and women aged 18 years or older, with body-mass index (BMI) 30 kg/m2 or greater, or BMI greater than 
27  kg/m2 with treated  or untreated hypertension or treated or untreated dyslipidaemia, were recruited from 60 
sites in Europe and the USA between October, 2001, and April, 2002. Although RIO-Europe was planned to be 
done in Europe only, difficulties in meeting recruitment targets led to the extension of the study to 20 sites in the 
USA with an enrolment, of 276 US patients. 
Eligible patients had less than 5 kg variation in body-weight within the 3 months before study entry. Exclusion 
criteria included clinical disorders, such as substantial endocrine disease, diabetes mellitus, cardiovascular or 
pulmonary disease, hepatic and renal disorders, or substantial neurological or psychological illness. Patients 
were also excluded if they had a history of depression necessitating hospitalisation, two or more recurrent 
episodes of depression, or suicide attempt. Previous history of surgical procedures for weight loss (eg, stomach 
stapling, bypass) was also an exclusion criterion. Concomitant use of medications known to alter bodyweight or 
appetite, including anti-obesity drugs, corticosteroids, antidepressants, neuroleptics, non-selective systemic 
antihistamines, nicotine substitutes, and antidiabetic drugs, was not permitted. No change in hypolipidaemic 
medication was allowed. To avoid metabolic effects due to altered smoking habits, patients who indicated their 
intention to stop smoking were not included. Marijuana and hashish users were excluded from the study. 
Figure 1: Trial profile *Including run-in period 
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Table 1: Baseline characteristics 
 Placebo (n=305) Rimonabant 5mg(n=603) Rimonabant 20mg(n=599) 
Race (white)* 290(95·1%) 565 (93·7%) 555(92·7%) 
Sex (female) * 244(80·0%) 476 (78·9%) 478 (79·8%) 
Age (years)† 45·0(11·6) 45·4(11·2) 44·6(11·9) 
BMI (kg/m2)† 35·7(5·9) 36·0(5·9) 36·2 (5·8) 
Weight (kg) † 100·0(20·3) 100·9 (19·8) 101·7(19·5) 
Waist (cm)† 107·7(13·8) 108·4(14·3) 108·8(14·1) 
Hypertension (%)* 116(38·0%) 264(43·8%) 237 (39·6%) 
Dyslipidaemia (%)* 189(62·0%) 371 (61·5%) 355 (59·4%) 
Metabolic syndrome (%)* 121(40·6%) 243 (40·8%) 251(42·4%) 
Current smokers (%)* 60 (19·7%) 136(22·6%) 102 (17·0%) 
*Data are number (%). †Data are mean(SD). 
Procedures 
The study was approved by the local ethics committees and done in accordance with the Declaration of Helsinki 
and ICH Good Clinical Practice between October, 2001, and June, 2004. RIO-Europe was a 2-year randomised, 
double-blind, placebo-controlled, parallel group, fixed-dose, multicentre study, with a 2-week screening period 
and 4-week single-blind, placebo run-in period. For the double-blind treatment period, the randomisation code 
list, with a block size of five, was generated centrally by the sponsor. Treatments were allocated to patients using 
the interactive voice responding system according to the predefined randomisation list (1: 2: 2 ratio for placebo, 
5 mg rimonabant, and 20 mg rimonabant, respectively). A central laboratory (ICON Laboratories, Farmingdale, 
USA, and Dublin, Ireland) ensured that the randomisation of treatment was balanced within each centre and was 
stratified based on the loss of bodyweight (≤2 kg or >2 kg) recorded during the run-in period, per protocol. 
During the double-blind period, patients were seen every 14 days during the first month and thereafter every  
28 days until the end of the study. 
Basal metabolic rate was estimated with the Harris Benedict formula, and 600 kcal were subtracted by a dietician 
to calculate a recommended daily energy intake for each patient. At each visit, patients received dietary 
counselling and were encouraged to increase physical activity. 
Bodyweight, waist circumference, and blood pressure were measured at screening, at randomisation, and at 
every treatment visit, whereas lipid profile, fasting glucose, and insulin were measured every 3 months by use of 
standard procedures in the central laboratory (ICON Laboratories).16 Hypertension was defined as 
systolic/diastolic blood pressure of 140/90 mm Hg or greater. Dyslipidaemia was defined as LDL-cholesterol 
3·36 mmol/L or greater, HDL-cholesterol less than 1·03 mmol/L, and triglycerides 1·69 mmol/L or greater. The 
prevalence of the metabolic syndrome was assessed at screening, baseline, and 12 months, according to the 
criteria of the National Cholesterol Education Program Adult Treatment Panel III.17 An oral glucose tolerance 
test (75 g glucose) was done at baseline and at 1 year. 
The primary efficacy endpoint was the absolute weight change from baseline (randomisation) at the end of  
year 1 in the intention-to-treat (ITT) population. Another weight-related criterion was the proportion of patients 
who achieved weight loss of 5% or more and 10% or more. Secondary efficacy endpoints were waist 
circumference (as a marker of change in abdominal obesity), concentrations of glucose and insulin in serum 
when fasting, HDL-cholesterol and triglycerides, and the prevalence of the metabolic syndrome. Additional 
efficacy endpoints were changes in concentrations of total cholesterol and LDL-cholesterol in serum and changes 
in insulin resistance, derived from the HOMA-IR (homoeostasis model assessment), calculated as fasting insulin 
(µU/mL) x fasting glucose (mmol/L)/22·5.18 Analysis of quality of life and dietary assessment were also done at 
baseline and after 1 year (data still under analysis). 
Safety assessments, including physical examination, standard laboratory tests (haematology, liver enzymes, 
blood chemistry tests), and an ECG, were done at screening, at baseline, and at regular visits every 3 months. 
Adverse events were recorded at each visit. Mood was evaluated with the Hospital Anxiety and Depression 
(HAD) scale19 at baseline and every 3 months. Patients who presented with a symptom of depression or an HAD 
score of 11 or greater had to be referred to a psychiatrist to ascertain the exact diagnosis of the clinical picture, 
and treatment if indicated. The HAD score is a short, self-report scale, which is easy to use in a primary-care 
setting to screen for the presence of mood disorders in different populations of patients, including obese 
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patients.19 An independent Data Safety Monitoring Board was in place to ensure the safety of the patients by 
review and analysis of the unblinded safety data, on a regular basis. 
Figure 2: Change from baseline in bodyweight (A) and waist circumference (B).Data are mean (SE) values for 
patients completing each scheduled visit, and LOCF (values for the full ITT population with the last observations 
carried forward). *p<0·001 vs placebo. †p=0·002 vs placebo. 
 
Statistical analysis 
For the primary endpoint, analysis was done in the ITT population using the last observation carried forward 
method and presented as mean and SD, unless otherwise stated. An analysis of variance (ANOVA) model, with 
treatment and randomisation strata as fixed effects, was used, followed by the modified Bonferroni procedure 
(Hochberg) to account for multiplicity of doses. For secondary endpoints, continuous variables were analysed by 
means of one-way ANOVA with treatment as fixed effect. Categorical variables were analysed with the χ2 test. 
Each rimonabant dose group was compared with the placebo group. 
Analysis of covariance (ANCOVA) and/or logistic regression models using weight loss as covariate were 
applied to investigate whether the observed effects on efficacy endpoints were independent of weight loss as 
reflected by the last weight measurement. All statistical tests were two-sided at the 5% significance level. 
Role of the funding source 
The study was designed by the steering committee, composed of the investigators of the RIO programme and a 
representative from the sponsor. The trial design and follow-up were assessed by the Trial Operational 
Committee. Data were collected by the pharmaceutical sponsor and were assessed jointly by the authors and the 
sponsor. The data were interpreted and the manuscript written by the authors. The corresponding author had full 
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Table 2: Changes in metabolic and cardiovascular risk factors in ITT population 
Placebo Rimonabant p vs placebo  
 
 
5mg 20 mg 5mg 20 mg 
Weight (kg) 
Baseline 99·9(20·2) 100·7(19·7) 101·7(19·4)   
1 year 98·1(20·9) 97·3(20·1) 95·1(20·6)   
Change -1·8(6·4) -3·4(5·7) -6·6(7·2) 0·002 <0·001 
Waist (cm) 
Baseline 107·7(13·8) 108·3(14·3) 108·7(14·1)   
1 year 105·3(14·3) 104·4(14·5) 102·2(15·4)   
Change -2·4(6·9) -3·9(6·3) -6·5(7·4) 0·002 <0·001 
SBP(mmHg) 
Baseline 126·8(13·7) 127·0(14·8) 127·0(14·1)   
1 year 127·0(13·6) 126·1(14·7) 126·0(14·1)   
Change 0·3(12·3) -0·9(12·5) -1·0(12·5) ns ns 
DBP (mmHg) 
Baseline 79·7(8·5) 79·6(9·1) 79·4(8·8)   
1 year 79·8(8·7) 78·8(8·9) 78·5(8·6)   
Change 0·1(8·5) -0·8(8·8) -0·9(8·7) ns ns 
TC(mmol/L) 
Baseline 5·29(1·00) 5·37(0·92) 5·37(1·00)   
1 year 5·37(1·01) 5·43(0·86) 5·42(0·98)   
Change 0·08(0·78) 0·06(0·70) 0·05(0·70) ns ns 
HDL-C(mmol/L) 
Baseline 1·27(0·34) 1·27(0·32) 1·27(0·33)   
1 year 1·42(0·38) 1·46(0·37) 1·54(0·40)   
Change 0·15(0·23) 0·19(0·23) 0·26(0·26) 0·048 <0·001 
TG(mmol/L) 
Baseline 1·45(0·87) 1·46(0·89) 1·45(0·85)   
1 year 1·43(0·78) 1·44(0·92) 1·25(0·72)   
Change -0·01(0·68) -0·02(0·77) -0·20(0·64) ns <0·001 
LDL-C(mmol/L) 
Baseline 3·13(0·82) 3·19(0·76) 3·21(0·81)   
1 year 3·30(0·88) 3·32(0·75) 3·29(0·83)   
Change 0·17(0·70) 0·13(0·62) 0·08(0·63) ns ns 
Total/HDL-C ratio 
Baseline 4·42(1·28) 4·46(1·22) 4·44(1·21)   
1 year 3·99(1·15) 3·94(1·11) 3·72 (1·06)   
Change -0·42(0·83) -0·52(0·80) -0·71(0·78) ns <0·001 
Fasting glucose (mmol/L) 
Baseline 5·26(0·70) 5·30(0·62) 5·28(0·70)   
1 year 5·29(0·83) 5·26(0·73) 5·20(0·68)   
Change 0·03(0·77) -0·05(0·68) -0·09(0·65) ns 0·026 
Fasting insulin (mU/mL) 
Baseline 12·4(9·6) 12·7(9·2) 12·7(9·5)   
1 year 14·2 (13·1) 13·0(10·5) 11·7(8·3)   
Change 1·8(13·0) 0·3(11·2) -1·0(8·8) ns <0·001 
HOMA-IR (%) 
Baseline 3·0(2·6) 3·1(2·8) 3·1(2·5)   
1 year 3·4(3·5) 3·1(2·9) 2·8(2·3)   
Change 0·4(3·5) 0·0 (3·4) -0·3(2·4) ns 0·002 
Data are mean (SD). Analyses for total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglycerides (TG) were 
done on percentage changes from baseline, and those for cholesterol ratios were done on changes from baseline. SBP=systolic blood 
pressure. DBP=diastolic blood pressure, ns=not significant. 
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Table 3: Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year 
follow-up 
 Placebo Rimonabant p vs placebo 
  
 
5 mg 20 mg 5 mg 20 mg 
Weight (kg) 
Baseline 98·5(197) 100·1(19·6) 102·0(19·7)   
1 year 94·9(20·0) 95·4(19·8) 93·4(20·8)   
Change -3·6(7·4) -4·8(6·2) -8·6(7·3) 0·042 <0·001 
Waist (cm) 
Baseline 108·0(13·8) 109·0(14·2) 109·3(14·4)   
1 year 103·5(14·3) 103·7(14·7) 100·8(15·5)   
Change -1·5(7·3) -5·3(6·4) -8·5(7·4) ns <0·001 
SBP (mmHg) 
Baseline 127·1(13·8) 127·4(14·7) 127·8(14·1)   
1 year 126·7(13·7) 126·1(15·1) 125·8(13·5)   
Change -0·4(12·7) -1·3(12·2) -2·0(12·6) ns ns 
DBP(mmHg) 
Baseline 80·2(8·0) 79·6(9·3) 79·7(9·0)   
1 year 79·8(8·2) 78·2(9·0) 78·0(8·5)   
Change -0·4(8·1) -1·5(8·8) -1·8(8·7) ns ns 
LDL-C(mmol/L) 
Baseline 3·12(0·81) 3·22 (0·77) 3·18(0·79)   
1 year 3·33(0·87) 3·36 (0·75) 3·28(0·82)   
Change 0·21(0·70) 0·13(0·61) 0·10(0·63 ns 0·024 
HDL-C(mmol/L)      
Baseline 1·28(0·37) 1·26(0·31) 1·27(0·33)   
1 year 1·48(0·41) 1·48(0·38) 1·59(0·41)   
Change 0·20(0·23) 0·23(0·23) 0·32(0·26) ns <0·001 
TG(mmol/L)      
Baseline 1·41(0·84) 1·45(0·88) 1·44(0·80)   
1 year 1·37(0·69) 1·42(0·92) 1·18(0·60)   
Change -0·04(0·68) -0·03(0·80) -0·26(0·60) ns <0·001 
Fasting glucose (mmol/L)      
Baseline 5·29(0·76) 5·37(0·64) 5·31(0·71)   
1 year 5·30(0·93) 5·30(0·68) 5·20(0·68)   
Change 0·01(0·90) -0·07(0·62) -0·11(0·66) ns ns 
Fasting insulin (mU/mL)     
Baseline 11·8(7·7) 12·7(10·3) 12·7(10·0)   
1 year 12·7(9·5) 12·5(8·2) 11·0(6·1)   
Change 1·0(8·7) -0·3(10·2) -1·7(8·8) ns 0·002 
HOMA-IR(%)      
Baseline 2·8(2·0) 3·1(3·2) 3·1(2·7)   
1 year 3·1(2·5) 3·0(2·3) 2·6(1·7)   
Change 0·3(2·2) -0·1(3·3) -0·5(2·4) ns 0·005 
Data are mean (SD). Analysesfortotal cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglycerides (TG) were 
done on percentage changes from baseline. SBP=systolic blood pressure. DBP=diastolic blood pressure, ns=not significant. 
Results 
309 men and 1198 women were randomised to double-blind treatment. 920 patients (61%) completed the 1-year 
follow-up: 178 (58·4%) in the placebo group, 379 (62·7%) in the rimonabant 5 mg group, and 363 (60·6%) in the 
rimonabant 20 mg group (figure 1). 
The treatment groups had similar demographic and baseline characteristics (table 1). 346 patients with a BMI of 
40 kg/m2 or greater were enrolled. At baseline, 617 (40·9%) patients had hypertension, 915 (60·8%) had 
dyslipidaemia, and 615 (41·4%) met the criteria for metabolic syndrome. During the 4-week run-in period, the 
mean decrease in weight across all groups was 1·9 kg (SD 2·2), with associated reductions of 1·5 cm (3·5) in 
waist circumference, 0·05 mmol/L (0·66) in triglyceride concentration, and 0·08 mmol/L (0·23) in HDL-
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cholesterol concentration. 
In the ITT population, change in bodyweight from baseline was significantly greater in the rimonabant 5 mg and 
20 mg groups than in the placebo group (figure 2A and table 2). Table 3 shows differences between the groups in 
patients who completed the allocated treatment. Taking into consideration the mean weight loss during the run-in 
period of 1 · 9 kg, total cumulative weight loss ranged from 5 kg in the placebo group to more than 10 kg in 
patients on rimonabant 20 mg. Waist circumference changed significantly from baseline in the rimonabant 5 mg 
and 20 mg groups (figure 2B, tables 2 and 3). 
Placebo-subtracted analysis showed that rimonabant 20 mg was associated with significant (all p<0·001) weight 
loss (mean -4·7 kg [SE 0·4] for ITT and -5·1 kg [0·6] for completers) and reduction in waist circumference (-4·2 
cm [0·5] and -4·0 cm [0·6]; data not shown). In the ITT population, a significantly greater proportion of patients 
in the rimonabant groups achieved weight loss of 5% or greater from baseline compared with the placebo group 
(figure 3A). The proportion of completers who had 10% or more weight loss was also greater in the rimonabant 
20 mg group than in the placebo group, but not different between the 5 mg group and placebo. A similar pattern 
of results was seen in completers (figure 3B). 
In morbidly obese patients (BMI ≥40 kg/m2), a similar effect on weight loss was recorded compared with the 
whole study population (data not shown). Results showed no interaction between sex and weight loss: no 
significant difference in changes was detected between men and women. 
Changes in metabolic and cardiovascular risk factors in the ITT population are shown in table 2. In this 
population, treatment with rimonabant 5 mg and 20 mg increased HDL-cholesterol by 16·2% (SE 0·8; p=0·048 
compared with placebo) and 22·3% (0·9; p<0·001), respectively, compared with 13·4% (1 · 1) in the placebo 
group (figure 4A). Triglyceride concentrations were reduced by 6·8% (SE 1·5; p<0·0001 vs placebo) in the 
rimonabant 20 mg group, compared with an increase of 5·7% (1·9) in the 5 mg group and 8·3% (2·6) in the 
placebo group, in the ITT population (figure 4B). Results in completers are presented in table 3. 
Logistic regression models and/or ANCOVA using weight loss as a covariate were applied to assess whether the 
effects of rimonabant 20 mg on both HDL-cholesterol and triglyceride at 12 months were partly independent of 
weight loss as reflected by the last weight measurement. The weight-loss-adjusted difference in HDL-cholesterol 
(expressed as the percentage change from baseline) between the placebo and rimonabant 20 mg groups was 3·6% 
(p=0·01 vs placebo), compared with an unadjusted difference of 8·9% (p<0·001 vs placebo); this value would 
translate to about 60% of the increase in HDL-cholesterol being accounted for by the observed weight loss in the 
ITT population. Similarly, the weight-loss-adjusted difference in the percentage change in triglyceride 
concentrations between placebo and rimonabant 20 mg was -8·3% (p=0·006 vs placebo) compared with the 
unadjusted difference of -15·1% (p<0·001 vs placebo) in the ITT population, corresponding to about 45% of the 
reduction being accounted for by the observed weight loss. 
A significant decrease in non-HDL-cholesterol was observed in the rimonabant 20 mg group compared with 
placebo (4·3% [SD 16·1] vs -0·2% [18·3]; p<0·001) in the ITT population; no difference was noted between the 
rimonabant 5 mg and placebo groups. Changes in LDL-cholesterol and total cholesterol were not significantly 
different between the rimonabant and placebo groups. 
In the ITT population, 1-year treatment with rimonabant 20 mg resulted in a significant reduction in fasting 
plasma glucose, compared with the placebo group (table 2). A similar pattern was observed for insulin 
concentration. A decrease from baseline in HOMA-IR was seen in the rimonabant 20 mg, whereas this index 
increased in the placebo group. No significant differences in fasting plasma glucose, fasting insulin, or HOMA-
IR, were noted between the rimonabant 5 mg group and placebo. Results for completers are presented in table 3. 
The proportion of patients with impaired glucose tolerance or diabetes during the oral glucose tolerance test at 
baseline who improved their glucose tolerance status was not different between groups. The 2-h post-load 
glucose concentrations were not statistically significant between groups. However, rimonabant 20 mg was 
associated with a significant reduction in 2-h insulin (-11·0 µU/mL [SD 40·1] from baseline vs -2·3 µU/mL 
[38·5] with placebo; p=0·019), a marker of insulin resistance. There were no significant differences in post-load 
insulin concentrations between rimonabant 5 mg and placebo. 
Overall, there were no interactions between sex and observed weight loss, changes in metabolic parameters, or 
reduction in waist circumference. Although the systolic and diastolic blood pressure were slightly reduced after 1 
year of rimonabant 20 mg treatment, the changes were not significantly different from placebo. 
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Figure 3: Proportion of patients who lost ≥5% and ≥10% of baseline weight at 1 year 
 
*p<0·001 vs placebo. †p=0·002 vs placebo. 
Figure 4: Mean percentage change from baseline in HDL-cholesterol (A) and triglycerides (B). Data are mean 
(SE) values for patients completing each scheduled visit, and LOCF (values for the full ITT population with the 
last observations carried forward).  
 
*p<0·001 vs placebo. †p=0·002 vs placebo. 
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The proportion of patients who fulfilled the criteria for the metabolic syndrome in the ITT and completer 
populations is shown in table 4. At 1 year from baseline, the proportion had decreased significantly more in the 
rimonabant 20 mg group than in the placebo group. 
The frequency of adverse events was slightly higher in the rimonabant 20 mg group than in the rimonabant 5 mg 
and placebo groups. Table 5 provides an analysis of all the adverse events occurring in at least 5% of patients in 
any group. The most common adverse events occurring with  rimonabant were:  nausea,  dizziness, arthralgia 
and diarrhoea, some patients exhibiting a higher incidence with rimonabant 20 mg. These events, however, were 
for the most part, mild to moderate in intensity and considered to be transient, based on the occurrence mainly 
during the first months of the study. There was more headache, fatigue, and upper respiratory infection in the 
placebo group. 
Similar frequencies of serious adverse events were reported in all groups: except for psychiatric disorders, no 
differences between the treatment groups were observed (tables 5 and 6). Two deaths were reported: one in the 
placebo group (haemorrhagic cerebrovascular accident, about 2·5 months after randomisation, in a 63-year-old 
woman treated with phenprocoumon for an aortic valve prothesis), and one in the rimonabant 20 mg group 
(diagnosis of uterine adenocarcinoma 2 months after randomisation in a 55-year-old woman, resulting in death 3 
weeks later due to complications). 
Table 4: Prevalence of the metabolic syndrome in the ITT and completer populations at baseline and after 1 
year of treatment 
 Placebo (%) Rimonabant 5 mg(%) Rimonabant 20 mg (%) 
ITT 
Baseline 108 of 271 (39·9%) 228 of 553 (41·2%) 228 of 540 (42·2%) 
1 year 85 of 271 (31·4%) 158 of 553 (28·6%) 106 of 540 (19·6%)* 
Change from baseline (%) 21·3% 30·6% 53·6%* 
Completers    
Baseline 65 of 167(38·9%) 155 of 366 (42·3%) 159 of 354 (44·9%) 
1 year 43 of 167 (25·7%) 101 of 366 (27·6%) 56 of 354 (15·8%)* 
Change from baseline (%) 33·9% 34·8% 64·8%* 
    
*p<0·001 rimonabant 20 mg vs placebo. 
The discontinuation rate was similar between the groups, with more withdrawals due to adverse events in the 
rimonabant 20 mg group and a higher rate of discontinuation due to lack of effect in the placebo group (figure 1). 
The most common adverse events leading to study discontinuation were depressed mood disorders in all 
treatment groups; discontinuations due to nausea, vomiting, diarrhoea, headache, dizziness, and anxiety were 
more frequent in the rimonabant 20 mg group than in the other groups (table 7). 
After 1 year, there were no significant changes in the HAD scale subscores for depression (placebo 2·7 [SD 2·9], 
rimonabant 5 mg 2·7 [2·7], and rimonabant 20 mg 3·4 [3·4]) or anxiety (4·4 [4·0], 4·5 [3·7], and 5·6 [4·1]). 
Similar proportions of patients with post-baseline depression subscores of 11 or greater were noted in the 
placebo (23, 8·5%), rimonabant 5 mg (40, 7·5%), and rimonabant 20 mg groups (41, 7·9%). No specific changes 
in laboratory parameters for haematology or kidney and liver functions were reported. No effect of rimonabant 
on blood pressure was noted (tables 2 and 3). Mean heart rate remained unchanged from baseline with 
rimonabant 20 mg, and QTcF decreased by 5·7 msec (SD 16·3) in the placebo group and 3·6 msec (16·9) in the 
rimonabant 20 mg group. 
Discussion 
In this study, treatment with rimonabant over 1 year led to sustained, clinically meaningful weight loss, reduction 
in waist circumference, and associated improvements in several cardiovascular and metabolic risk factors, 
including HDL-cholesterol and triglyceride concentrations, HOMA-IR, and prevalence of the metabolic 
syndrome. About half of the effect of rimonabant on HDL-cholesterol and triglycerides was independent of 
weight loss. Despite a significant effect on bodyweight, rimonabant 5 mg had an effect of limited clinical interest 
on metabolic variables. More than 67% of patients who completed treatment with rimonabant 20 mg achieved 
5% or more weight loss, and 39% achieved 10% or more weight loss; the target of 5-10% weight loss, which is 
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judged to be standard in the field of conventional obesity treatment, could be achieved.20,21 The pattern of weight 
loss observed in this study with rimonabant appears to be sustained up to 36-40 weeks. How this finding would 
translate into prolonged weight loss in clinical practice has to be determined. The decrease in waist 
circumference, a measure of abdominal obesity, is known to be associated with improvements in cardiovascular 
disease risk factors,22,23 including atherothrombotic and proinflammatory metabolic abnormalities.24 The weight 
loss observed in 39% of patients treated with rimonabant 20 mg was associated with a concomitant reduction in 
waist circumference by about 9 cm, a value that could be associated with a 30% decrease in intra-abdominal 
adiposity.24
Rimonabant treatment was associated with significant improvements in lipid and glycaemic variables. 
Importantly, the improvements in HDL-cholesterol and triglycerides observed in this study could not be fully 
explained by the observed weight loss alone; this statement is supported by the changes over time in these 
metabolic variables compared with bodyweight. The marked increase of HDL-cholesterol among placebo-treated 
patients can partly be explained by the fact that, during the run-in period, HDL-cholesterol decreased by about 
6% (data not shown) as a logical consequence of the negative energy balance during that period. Irrespective of 
this effect, the placebo-subtracted benefit in HDL-cholesterol increase with rimonabant reached about 10%. In 
view of the knowledge that a 1% increase in HDL-cholesterol might lead to a 2% reduction in cardiovascular 
risk, these findings seem to be promising.25
The endocannabinoid system is a neuromodulatory system that plays a role in many physiological processes, 
including the regulation of food intake and energy homoeostasis.5 Over the past decade, understanding of 
endocannabinoid biology has progressed substantially with the identification of two G protein-coupled 
cannabinoid receptors, CBB1 and CB2,  and their endogenous ligands. CB26,27 1 receptors are located in the central 
nervous system and in various peripheral tissues.  CB28 2 receptors are located in the immune system and do not 
seem to have a role in energy homoeostasis. Rimonabant is a selective CB129 B  blocker that suppresses tonic 
endogenous activation of the endocannabinoid system centrally4,6 and peripherally8,30 (figure 5). 
Rimonabant reduces the excessive consumption of palatable food or drinks in rats and marmosets.31,32 The 
mechanism by which rimonabant regulates food intake is probably centrally mediated,15 but recent results 
suggest an additional peripheral action. Indeed, endocannabinoids derived from the gastrointestinal tract appear 
to be able to modulate feeding behaviour by acting on CBB1 receptors located on capsaicin-sensitive sensory 
terminals.  In diet-induced obese mice, rimonabant treatment leads to a marked and sustained reduction of 11
bodyweight and adiposity that could not be explained by the transient reduction of food intake observed. When 
compared with food restriction in a pair-feeding protocol, rimonabant treatment induced a greater bodyweight 
loss in diet-induced obese mice, indicating that the effects of rimonabant on bodyweight are partly independent 10 
of food intake. It seems likely that CB1 receptors expressed on adipocytes might be one of the effectors of the 
possible peripheral metabolic action of rimonabant. 
Table 5: Patients reporting adverse events (≥5% in any treatment group) 
 Placebo (n=305) Rimonabant 5 mg (n=603) Rimonabant 20 mg (n=599)
Any adverse events 257 (84·3%) 498(82·6%) 522 (87·1%) 
Nasopharharyngitis 48 (15·7%) 87 (14·4%) 93 (15·5%) 
Influenza 32 (10·5%) 51(8·5%) 54(9·0%) 
Gastroenteritis 24(7·9%) 40 (6·6%) 51(8·5%) 
Upper respiratory tract infection 23 (7·5%) 43(7·1%) 33 (5·5%) 
Bronchitis 16(5·2%) 34(5·6%) 34(5·7%) 
Sinusitis 17 (5·6%) 27 (4·5%) 26 (4·3%) 
Headache 41 (13·4%) 58 (9·6%) 59 (9·8%) 
Dizziness 15 (4·9%) 42 (7·0%) 52 (8·7%) 
Nausea 13 (4·3%) 31(5·1%) 77(12·9%) 
Diarrhoea 9 (3·0%) 36 (6·0%) 43(7·2%) 
Arthralgia 21(6·9%) 58 (9·6%) 47 (7·8%) 
Back pain 26 (8·5%) 56 (9·3%) 55(9·2%) 
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Table 6: Serious adverse events by system organ class during the double-blind period of the trial 




Any serious adverse event 23 (7·5%) 45 (7·5%) 52 (8·7%) 
Respiratory disorders 0 0 2 (0·3%) 
Psychiatric disorders 1 (0·3%) 2 (0·3%) 9 (1·5%) 
Nervous system disorders 3 (1·0%) 7(1·2%) 3 (0·5%) 
Ear disorders 0 0 1(0·2%) 
Cardiac disorders 0 2 (0·3%) 2 (0·3%) 
Vascular disorders 0 2 (0·3%) 3 (0·5%) 
Gastrointestinal disorders 3 (1·0%) 3 (0·5%) 2 (0·3%) 
Hepatobiliary disorders 3 (1·0%) 5 (0·8%) 1(0·2%) 
Musculoskeletal and connective disorders 6(2·0%) 13(2·2%) 10 (1·7%) 
Renal and urinary disorders 0 2 (0·3%) 2 (0·3%) 
Reproductive system and breast disorders 1 (0·3%) 2 (0·3%) 3 (0·5%) 
Investigations 1 (0·3%) 0 1(0·2%) 
Injury, poisoning, and procedure 
complications 
4(1·3%) 5 (0·8%) 4 (0·7%) 
Neoplasms: benign, malignant, and 
unspecified 
2 (0·7%) 5 (0·8%) 7(1·2%) 
General disorders 0 0 1(0·2%) 
Data are proportions of patients with at least one serious event. 
Table 7: Patients reporting adverse events leading to discontinuation 




Any adverse event leading to 
discontinuation 
28(9·2%) 50 (8·3%) 87 (14·5%) 
Psychiatric disorders 16(5·2%) 18 (3·0%) 42 (7·0%) 
Depressed mood disorders 9 (3·0%) 14(2·3%) 22 (3·7%) 
Anxiety 1 (0·3%) 0 6(1·0%) 
Agitation 2 (0·7%) 0 3 (0·5%) 
Sleep disorders 0 2 (0·3%) 1(0·2%) 
Nervous system disorders 2 (0·7%) 8 (1·3%) 10 (1·7%) 
Headache 0 2 (0·3%) 4 (0·7%) 
Dizziness 0 2 (0·3%) 2 (0·3%) 
Hypoaesthesia 0 0 2 (0·3%) 
Gastrointestinal disorders 0 5 (0·8%) 21(3·5%) 
Nausea 0 1 (0·2%) 14(2·3%) 
Vomiting 0 0 4(0·7%) 
Diarrhoea 0 0 3 (0·5%) 
Dyspepsia 0 0 2 (0·3%) 
Flatulence 0 2 (0·3%) 0 
Cardiac disorders 3 (1·0%) 2 (0·3%) 5 (0·8%) 
Palpitations 1 (0·3%) 0 2 (0·3%) 
According to the Medical Dictionary for Regulatory Activities in at least two patients in any treatment group (one patient may report several 
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Figure 5: Hypothetical model of role of central and peripheral components of endocannabinoid system in 
regulation of food intake and peripheral metabolism. CB1 receptors are enriched in regions of the brain and in 
gastrointestinal system implicated in the regulation of food intake, and in adipose tissue. CB1 receptor blockade 
might contribute to decreased food intake and exert direct metabolic effects. 
 
A possible explanation for the potential weight-independent effect of rimonabant on HDL-cholesterol and 
triglycerides might be related to the observation that rimonabant enhances the mRNA expression of adiponectin, 
an adipokine secreted by fat cells and reported to have a role in the regulation of hyperglycaemia, 
hyperinsulinaemia, and fatty acid oxidation,33-36 at the peripheral adipocyte level.8 Thus, improved fat-cell 
function may be postulated as a key peripheral effect of rimonabant leading to bodyweight reduction and 
improvement in metabolic parameters, including lipids and beneficial changes in adiponectin and C-reactive 
protein. Further studies of the in-vivo effects of the increased adiponectin production induced by rimonabant 
treatment are needed to elucidate possible metabolic effects of rimonabant in adipose tissue. 
Rimonabant treatment was well tolerated during this trial, with a similar overall drop-out rate in all treatment 
groups. The most common adverse events experienced with rimonabant 20 mg, such as nausea and diarrhoea, 
were found to be mild and generally occurred in the first few  months  of the  treatment.  Gastrointestinal  side-
effects might be explained by the mechanism of action of the drug, since it is known that CB1 receptors are 
present in the gut and likely to be involved in gastrointestinal motility. Serious adverse events did not seem to 
occur more frequently in the patients treated with rimonabant than in those on placebo. Mood disorders were 
more frequent in the rimonabant 20 mg treatment group than in the other groups, but the discontinuation rate due 
to this adverse event was similar between rimonabant 20 mg and placebo in this study. 
The RIO-Europe trial was designed to reflect a real-life clinical setting in which we assessed parameters 
indicative of the metabolic syndrome and relevant clinical endpoints, such as waist circumference, in patients 
with a range of pre-existing risk factors. The 1-year results emphasise that blockade of the CBB1 receptor clearly 
targets several causes of cardiovascular risk, including obesity and the metabolic syndrome, along with its 
associated parameters such as waist circumference, HDL-cholesterol, and insulin resistance. The prevalence of 
the metabolic syndrome, compared with baseline, was reduced by more than half in the ITT population and by 
almost two-thirds in completers. There has been an increased awareness of the importance of this syndrome and 
its relation to cardiovascular disease in recent years. The large number of patients treated with CB1 blockade who 
achieved the 10% target for weight loss or had a marked improvement in the top risk factors established by the 
world-wide INTERHEART study, suggests that rimonabant can be considered as a valuable adjunct therapy for 37 
weight and waist reduction in patients at high cardiovascular risk. 
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The finding of a significant reduction in the incidence of the metabolic syndrome after 1 year of treatment with 
rimonabant 20 mg could have further implications, since the metabolic syndrome has been shown to be an 
important predictor of the development of type 2 diabetes and coronary heart disease.38,39 However, the long-
term benefits of weight loss and treatment of the metabolic syndrome on the prevention of cardiovascular events 
and mortality have yet to be confirmed by long-term outcomes studies. 
In conclusion, the results of the RIO-Europe trial indicate that modulating the activity of the endocannabinoid 
system by blocking its CBB1 receptors holds therapeutic promise as an approach to the treatment of obesity and 
associated risk factors. Treatment with rimonabant was associated with clinically meaningful weight loss and 
additional improvements in waist circumference, lipid concentrations, and insulin resistance, and had a 
favourable safety profile. 
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